Last mentioned: Mar 23, 2026
JPM Earnings
JPMorgan Chase reports Q1 results amid regulatory and legal headwinds.
FDA Decision Date
Expected regulatory ruling on orforglipron oral weight loss drug.
Zepbound Approval
FDA expands tirzepatide approval to include chronic weight management.
Mounjaro Launch
Tirzepatide enters the market for Type 2 Diabetes treatment.
Eli Lilly (LLY) is approaching a pivotal April 10 regulatory milestone for orforglipron, its experimental oral GLP-1 receptor agonist, as it seeks to expand its $11 billion weight-loss portfolio. While the broader market faces volatility from the banking sector's upcoming earnings on April 14, the biotech industry is laser-focused on the potential shift from injectable to oral metabolic therapies.
Eli Lilly has identified hazardous impurities in unapproved, compounded versions of its blockbuster weight-loss drugs, Mounjaro and Zepbound. The pharmaceutical giant is warning patients and providers about significant safety risks as compounding pharmacies continue to exploit ongoing supply shortages.
As market volatility persists in early 2026, Eli Lilly and Veeva Systems emerge as top growth picks driven by the obesity drug boom and AI integration. With Eli Lilly's tirzepatide securing its spot as the world's top-selling drug and new oral GLP-1s on the horizon, the pharmaceutical landscape is shifting toward tech-heavy, high-margin innovation.
This page surfaces every story mentioning tirzepatide across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where tirzepatide was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |